Table 2.
Primary and Secondary Outcomes.
| Pre-Intervention (n = 81) |
Post-Intervention (n = 79) |
p Value | |
|---|---|---|---|
| HSV PCR TAT, hours, median (IQR) | 85 (77–99.6) | 4.1 (2.9–5.4) | <0.001 |
| VZV PCR TAT, hours, median (IQR) | 124.1 (102–152.3) | 4.1 (2.9–5.4) | <0.001 |
| Enterovirus PCR TAT, hours, median (IQR) | 112.4 (87.2–140.2) | 4.1 (2.9–5.4) | <0.001 |
| CMV PCR TAT, hours, median (IQR) | 98.4 (79.6–123.4) | 4.1 (2.9–5.4) | <0.001 |
| Total antiviral DOT, median (IQR) | 3 (1–5) | 1 (0–2) | <0.001 |
| Total antiviral DOT if negative HSV/VZV PCR, median (IQR) | 2 (1–5) | 1 (0–2) | <0.001 |
| Total antimicrobial DOT, median (IQR) | 7 (4–13) | 5 (1–9.5) | <0.001 |
| LOS, days, mean ± SD | 6.6 ± 7.6 | 4.4 ± 3.5 | 0.02 |
Abbreviations: HSV: Herpes simplex virus, PCR: Polymerase chain reaction, TAT: Turnaround time, IQR: Interquartile range, CMV: Cytomegalovirus, VZV: Varicella-zoster virus, LOS: Length of stay, DOT: Days of therapy, SD: Standard deviation.